Navigation Links
New Molecule Discovery Shows Promise Against Tamoxifen-Resistant Breast Cancers
Date:6/16/2008

Potential therapy could be the next generation of treatments, researchers say

MONDAY, June 16 (HealthDay News) -- Researchers have identified a new group of compounds that might one day be added to the armamentarium of therapies designed to fight estrogen-fueled breast cancer.

"This is a potential new approach to treating hormonally sensitive tumors," said Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society. "If it proves to work with a lot of further research, then it does have potential as an important part of cancer research."

The study, by researchers from the University of North Carolina, Chapel Hill, the University of Colorado Health Sciences Center, Denver, and the University of Illinois, Urbana-Champaign, was presented Monday at the annual meeting of the Endocrine Society, in San Francisco.

The molecule, called TPBM, and related drugs may have a role in treating patients who have become resistant to other hormone-based therapies, such as tamoxifen.

"We have a large number of people who have estrogen receptor-positive breast cancer who respond wonderfully to hormone therapy. But, sometimes, after one or two years, the hormone therapy stops working," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La. "[Then] we'll switch to something else. That works for about a year before the cancer progresses. So what is it that's happening in those cancer cells that they become resistant? Perhaps there is another mechanism in which we can try to keep cells in response, and this would perhaps be one of them."

Some two-thirds of all breast cancers are estrogen receptor-positive and therefore respond to hormonal treatments such as tamoxifen or the newer aromatase inhibitors.

Tamoxifen blocks estrogen receptors on breast cancer cells, while aromatase inhibitors interfere with the body's ability to produce estrogen.

But almost all cancers in this category eventually become resistant to tamoxifen and, in some cases, tamoxifen may even turn the tables and start acting like estrogen, thereby fueling tumor growth.

Through extensive laboratory testing, the study authors identified a group of compounds related to TPBM that interfered with estrogen's effect on breast cancer cells via a different pathway. The molecules work by affecting the way estrogen receptors interact with a woman's DNA, the researchers said.

TPBM has the advantage of being "highly specific" and therefore much less likely to have any unwanted effects on other cells. It also works against tamoxifen when tamoxifen starts fueling tumor growth, the researchers said.

"As we look forward with all of our research and our capabilities, we'll hopefully continue to discover new ways to exploit hormone sensitivity," Lichtenfeld said. "This may be the next pathway, although we can't say that for sure... Hormonal approaches to breast cancer continue to add, literally, years to lives."

More information

For more on treating breast cancer, visit the National Cancer Institute.



SOURCES: Jay Brooks, M.D., chairman of hematology/oncology, Ochsner Health Service, Baton Rouge, La.; Len Lichtenfeld, M.D., deputy chief medical officer, American Cancer Society, Atlanta; June 16, 2008, presentation, The Endrocine Society annual meeting, San Francisco


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New class of RNA molecules may be important in human cancer
2. Molecule Promising Against Huntingtons Disease
3. Free Access to Literature Data on Chagas Disease Offered Online: Collaborative Drug Discovery, Inc. provides Neglected Disease researchers with archive mine and collaborate access to small molecule bioactivity SAR data on parasitic disease
4. Vulnerability to Stress Linked to Brain Molecule
5. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
6. Study Describes Molecules That Control Blood Pressure
7. Researchers identify molecules with interesting anti-clotting properties
8. Jefferson neuroscientists show anti-inflammation molecule helps fight MS-like disease
9. St. Jude finds molecule that could improve cancer vaccines and therapy for other diseases
10. Major Advance in the Observation of DNA Molecules
11. Molecules can block breast cancers ability to spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 16, 2017 , ... Permobil has just completed ... of custom seating systems has a well-earned reputation for premium quality, with a ... innovation and growth in the custom seating business, which enjoys strong demand, and ...
(Date:1/16/2017)... CA (PRWEB) , ... January 16, 2017 , ... ... manuscript in the Aesthetic Surgery Journal , the official journal of The ... conducted on lower eyelid retraction surgery. The procedure is designed to correct drooping, ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... NexTec Group ... a group of 100 organizations honored for their accomplishments in the field of midmarket ... growth, industry leadership and recognition, and innovation. Selection is not based on revenue and ...
(Date:1/15/2017)... ... January 15, 2017 , ... "On Tour is a music themed ... and ease," said Christina Austin - CEO of Pixel Film Studios. , On ... edit the style and animation of their slideshows. Place each slide on top of ...
(Date:1/14/2017)... ... 2017 , ... Healthy living brand Moody Zook recently came ... With more and more people opting to go organic in their lifestyle, the ... to specific needs. , Moody Zook focused particularly on their newly launched activated ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... Stock-Callers is currently reviewing the following Medical Appliances ... WMGI ), Varian Medical Systems Inc. (NYSE: VAR ... NuVasive Inc. (NASDAQ: NUVA ). These companies belong ... finish on Thursday, January 12 th , 2017, with the ... health care companies in the S&P 500 were down less ...
(Date:1/13/2017)... , Jan. 13, 2017  Alfalfa, cattle, leafy greens and ... environmental sampling film , which emphasizes the food industry,s shift ... highlights how COPAN,s Swab Rinse Kit ... the surface sampling process in the wake of the new ... COPAN is expanding the U.S. production ...
(Date:1/13/2017)... 13, 2017 On Thursday, January ... Average, and the S&P 500 edged lower at the ... trading session in bearish territories. Taking into consideration yesterday,s ... this morning: Myriad Genetics Inc. (NASDAQ: MYGN ... Research Holdings Inc. (NASDAQ: INCR ), and ...
Breaking Medicine Technology: